Literature DB >> 31123819

Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).

Shinya Suzuki1, Yoshiyuki Morishima2, Atsushi Takita3, Naoharu Yagi4, Takayuki Otsuka4, Takuto Arita4, Takeshi Yamashita4.   

Abstract

The aims of this study were to determine the distribution of plasma concentration of edoxaban (PC-Ed) with their 90% interval (on therapy range) and its correlation with anticoagulation markers in patients with non-valvular atrial fibrillation (NVAF). Consecutive 97 NVAF patients under edoxaban therapy were evaluated (60/30 mg dose, n = 48/49; men/women, n = 71/26; age, 69 years). CHADS2 score 0, 1, and ≥ 2 were 27%, 44%, and 29%, respectively. The mean (90% interval) of PC-Ed by LC-MS/MS was 194.3 (49.4-345.3) and 17.0 (4.8-40.7) ng/mL at peak (2-4 h post-dose) and trough (pre-dose), respectively. Correlation of prothrombin time (PT) with PC-Ed was higher than that of activated partial thromboplastin time (aPTT). Among 6 PT reagents, Coagupia PT-N and Simplastin Excel S (both PT reagents) showed the highest predictive capability for the upper outlier of PC-Ed at peak and trough. Among 4 aPTT reagents, only Thrombocheck APTT measured at peak had a significant predictive capability. When using PT reagents, both peak and trough sampling showed a similar predictive capability for the upper outliers of PC-Ed with a high sensitivity, but a relatively low specificity. We demonstrated the distributions of plasma concentration, PT with 6 reagents, and aPTT with 4 reagents under edoxaban therapy in Japanese patients with NVAF, showing their 90% intervals. For predicting the upper outlier of PC-Ed, PT was more sensitive compared with aPTT, whereas predicting capability for the outliers of PC-Ed was mostly similar between peak and trough samplings among PT reagents (UMIN 000032492).

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Edoxaban

Mesh:

Substances:

Year:  2019        PMID: 31123819     DOI: 10.1007/s00380-019-01438-6

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  26 in total

1.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

2.  Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.

Authors:  Jonathan Douxfils; Bernard Chatelain; Christian Chatelain; Jean-Michel Dogné; François Mullier
Journal:  Thromb Haemost       Date:  2015-10-29       Impact factor: 5.249

3.  Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.

Authors:  Ophelia Q P Yin; Raymond Miller
Journal:  Clin Drug Investig       Date:  2014-10       Impact factor: 2.859

4.  Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.

Authors:  Mohinder S Bathala; Hiroshi Masumoto; Toshihiro Oguma; Ling He; Chris Lowrie; Jeanne Mendell
Journal:  Drug Metab Dispos       Date:  2012-08-30       Impact factor: 3.922

5.  In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

Authors:  Meyer Michel Samama; Jeanne Mendell; Céline Guinet; Léna Le Flem; Satoshi Kunitada
Journal:  Thromb Res       Date:  2011-08-17       Impact factor: 3.944

6.  Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.

Authors:  Jeffrey I Weitz; Stuart J Connolly; Indravadan Patel; Daniel Salazar; Shashank Rohatagi; Jeanne Mendell; Helen Kastrissios; Jianqing Jin; Satoshi Kunitada
Journal:  Thromb Haemost       Date:  2010-08-05       Impact factor: 5.249

Review 7.  Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.

Authors:  Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

8.  Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; David A Morrow; Sabina A Murphy; Julia F Kuder; Naveen Deenadayalu; Petr Jarolim; Joshua Betcher; Minggao Shi; Karen Brown; Indravadan Patel; Michele Mercuri; Elliott M Antman
Journal:  Lancet       Date:  2015-03-11       Impact factor: 79.321

9.  DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.

Authors:  T Furugohri; K Isobe; Y Honda; C Kamisato-Matsumoto; N Sugiyama; T Nagahara; Y Morishima; T Shibano
Journal:  J Thromb Haemost       Date:  2008-07-04       Impact factor: 5.824

10.  Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.

Authors:  Ophelia Q P Yin; Kimura Tetsuya; Raymond Miller
Journal:  Eur J Clin Pharmacol       Date:  2014-08-29       Impact factor: 2.953

View more
  1 in total

1.  Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7).

Authors:  Shinya Suzuki; Yoshiyuki Morishima; Atsushi Takita; Takayuki Otsuka; Naoharu Yagi; Takuto Arita; Takeshi Yamashita
Journal:  Heart Vessels       Date:  2019-09-14       Impact factor: 2.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.